Cancer patients who receive COVID boosters are far less likely to be hospitalized, but vaccination rates remain alarmingly low, researchers report.

Despite offering significant protection against severe COVID-19, patients with cancer, a high-risk group, showed low uptake of booster vaccinations.

Cancer is a broad term used to describe the uncontrollable proliferation of mutated cells deleterious to the body. Any tissue in the body can become mutate | Immunology ...

Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Fact checked by Nick Blackmer Karen Peterson was diagnosed with stage 1 triple-negative breast cancer in 2015. After undergoing three months of chemotherapy with difficult side effects, she made the ...

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic ...

Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...